Capmatinib
CINC280A2301
Phase 3 small_molecule terminated
Quick answer
Capmatinib for Carcinoma, Non-Small-Cell Lung is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Carcinoma, Non-Small-Cell Lung
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated